BioCell Innovations Pte Ltd has recently signed a Memorandum of Understanding with Thermo Fisher Scientific Pte Ltd (a subsidiary of Thermo Fisher Scientific Inc) aiming to optimize a closed process for the clinical manufacturing of lentiviral-based immunotherapies within the Asia-Pacific region. We are excited to collaborate and to support new opportunities by bringing together BioCell Innovtions’ expertise in developing CAR lentiviral vectors with Thermo Fisher Scientific’s solutions for a closed, modular cell processing, thus accelerating pipelines from research to clinical and commercial manufacturing.